Open clinical references
Variant cheat sheets
One-page references for the variants oncologists and pathologists encounter most often. AMP/ASCO/CAP 2017 tiers, FDA-approved companion diagnostics, and resistance pathways. Citations point to CIViC, ClinVar, ClinicalTrials.gov, openFDA, and primary literature you can verify yourself.
Free. No signup. Decision-support aid only, not a CAP/CLIA-validated diagnostic.
- Lung
EGFR mutations in NSCLC
L858R, exon 19 del, exon 20 ins, T790M. First-line targeted therapy by mutation class, resistance pathways, FDA-approved companion diagnostics.
Open cheat sheet →
- Melanoma
BRAF mutations in melanoma
V600 vs class II/III BRAF, doublet and triplet combinations, when single-agent BRAF inhibition is harmful.
Open cheat sheet →
- Lung
KRAS G12C in NSCLC
Sotorasib and adagrasib post-platinum, resistance via secondary KRAS mutations and bypass amplifications, STK11/KEAP1 co-mutation modifiers.
Open cheat sheet →
- Lung
ALK fusions in NSCLC
Alectinib vs lorlatinib as first-line, CROWN long-term data, G1202R resistance, CNS efficacy comparison.
Open cheat sheet →
- Lung
ROS1 fusions in NSCLC
Repotrectinib (TRIDENT-1), entrectinib, crizotinib. G2032R resistance. CNS coverage.
Open cheat sheet →
- Lung
MET exon 14 skipping in NSCLC
Capmatinib (GEOMETRY mono-1) and tepotinib (VISION). RNA-based detection. Distinct from MET amplification.
Open cheat sheet →
- Lung / Thyroid
RET fusions in NSCLC and MTC
Selpercatinib and pralsetinib. Tumor-agnostic RET indication. Selective vs multikinase inhibitors.
Open cheat sheet →
- Lung
HER2 (ERBB2) mutations in NSCLC
T-DXd for HER2 exon 20 insertions (DESTINY-Lung01/02). Distinct from HER2 amplification.
Open cheat sheet →
- Breast
HER2-positive breast cancer
Trastuzumab + pertuzumab + taxane 1L, T-DXd 2L (DESTINY-Breast03), HER2-low expansion (DESTINY-Breast04).
Open cheat sheet →
- Breast
PIK3CA in HR+/HER2- breast
Alpelisib (SOLAR-1), inavolisib (INAVO120), capivasertib (CAPItello-291). Hyperglycemia management.
Open cheat sheet →
- Gyn
BRCA1/2 in ovarian cancer
Olaparib (SOLO-1, PAOLA-1), niraparib (PRIMA), rucaparib (ARIEL3). HRD-positive expansion.
Open cheat sheet →
- GU
BRCA2 in metastatic prostate
Olaparib (PROfound), talazoparib + enzalutamide (TALAPRO-2), niraparib + abiraterone (MAGNITUDE).
Open cheat sheet →
- GI
BRAF V600E in colorectal
Encorafenib + cetuximab (BEACON CRC). Why BRAFi monotherapy fails in CRC. MSI co-testing.
Open cheat sheet →
- Heme
IDH1/IDH2 in AML
Ivosidenib + azacitidine 1L (AGILE), enasidenib, olutasidenib. Differentiation syndrome.
Open cheat sheet →
- Heme
FLT3 in AML
Midostaurin (RATIFY), quizartinib (QuANTUM-First), gilteritinib (ADMIRAL, MORPHO). ITD allelic ratio.
Open cheat sheet →
- Tumor-agnostic
NTRK fusions pan-tumor
Larotrectinib, entrectinib, repotrectinib (TRIDENT-1). Tumor-agnostic FDA indication.
Open cheat sheet →
- Tumor-agnostic
MSI-H / dMMR pan-tumor
Pembrolizumab tumor-agnostic (KEYNOTE-158). Lynch syndrome workup. dMMR endometrial (dostarlimab).
Open cheat sheet →
Related references
Looking for pharmacogenomic dosing guidance? See the CPIC-aligned PGx pages. Looking for active clinical trials by gene? See the trial-by-gene index. Want one specific to your workflow? Tell us.
Working with vendor reports daily?
UNMIRI's pathologist tool unifies Foundation Medicine, Tempus, Caris, Guardant, and other vendor PDFs into one normalized view. Free for individual clinical use.
Join the pathologist beta →